65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy

Natasha B. Leighl, Luis Paz‐Ares, Delvys Rodríguez‐Abreu, Rina Hui, Sofia Baka, Frédéric Bigot, Makoto Nishio, Alexey Smolin, S. Ahmed, Adam J. Schoenfeld, S. Daher, Diego Cortinovis, V.P. Di Noia, Helena Linardou, Justin F. Gainor, Chinyere E. Okpara, Xuan Deng, Debra Kush, Andrew Song, Byoung Chul Cho